Document is current

Any future updates will be listed below

Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients

Crossref DOI link: https://doi.org/10.1007/s10067-015-3135-3

Published Online: 2015-12-03

Published Print: 2016-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark